Live Longer, Better

This disparity is driven primarily by the rising prevalence of noncommunicable diseases such as musculoskeletal and neurological conditions, as well as mental health challenges. In practical terms, it means that many Australians spend the final decade or more of their lives managing illness, disability, and declining function rather than thriving.

In Australia, coronary heart disease remains the leading underlying cause of death, followed by dementia including Alzheimer’s disease, cerebrovascular disease including stroke, lung cancer, and chronic obstructive pulmonary disease. These conditions rarely arrive without warning. They are preceded by years of detectable, modifiable risk.

The goal of longevity medicine and healthy ageing is not simply to extend the number of years on the calendar. It is to close the healthspan gap: to add years of vibrant, capable, cognitively sharp living, and to compress the period of serious decline into as short a window as possible at the very end of life. This concept is sometimes called the “compression of morbidity,” and it is at the heart of everything we do at Duro Health.

Enter Medicine 3.0

Medicine 3.0 represents a fundamental shift in how we think about health. Where Medicine 2.0 asks “are you sick?”, Medicine 3.0 asks “what is your risk, and what can we do about it now, years or decades before disease takes hold?”

The key distinctions are:

Medicine 2.0 uses population-average reference ranges to determine whether a result is “normal.” It is reactive by design, triggered by symptoms or acute presentations. It applies the average risk of a population group to an individual, which is often a poor fit. It is incentivised by the diagnosis and treatment of established disease.

Medicine 3.0 uses optimal ranges derived from longevity and preventive medicine research, levels associated with thriving rather than merely surviving. It is proactive, seeking to identify and address risk years before disease emerges. It treats each person as a unique individual with their own genetic landscape, history, goals, and risk profile. It asks not just “what is your result?” but “what does this result mean for you, and what are we going to do about it?”

At Duro Health, this philosophy is built into every consultation. We do not wait for signs and symptoms. We go looking, deliberately, systematically, and early.

A Personalised, In-Depth Assessment Changes Everything

One of the most powerful arguments for deep, personalised health assessment is this: the information changes what you do. Knowing that you are at elevated cardiovascular risk, or that your biological age is running ahead of your chronological age, or that a specific metabolic pathway is quietly dysregulated, gives you something that a generic health check cannot: a specific, actionable reason to act.

Research consistently shows that personalised risk information significantly improves health decision-making. When people understand their individual risk in concrete, meaningful terms, rather than being told they are “in the normal range,” they are better equipped to make informed choices about their lifestyle, their investigations, and their treatment preferences. They move from passive recipients of care to active participants in their own health.

This is why Duro Health’s assessments go well beyond a standard check-up, and why every plan we create is tailored to the individual in front of us, not the average patient on a population chart.

Four Examples: What We Look For and Why

1. ApoB: The Cardiovascular Risk Marker Your Standard Check-Up Probably Missed

   Most people who receive a standard blood test are given a total cholesterol result and perhaps an LDL cholesterol figure. These numbers have their uses, but they miss something important.

   Apolipoprotein B (ApoB) is a protein that coats every atherogenic (artery-hardening) particle in the blood. While LDL cholesterol measures the amount of cholesterol carried in LDL particles, ApoB directly counts the number of those particles. And it is the number of particles, not just the cholesterol they carry, that drives arterial plaque formation.

   ApoB is known to be a more powerful predictor of cardiovascular disease than conventional lipids, and large prospective studies have confirmed this. In the Swedish AMORIS cohort study of 137,100 men and women followed for an average of 17.8 years, elevated ApoB was associated with significantly increased risk of major adverse cardiovascular events, and abnormal values were detectable decades before such events developed.

   This last point is critical. ApoB can be elevated, silently, while your standard cholesterol panel looks perfectly acceptable. At Duro Health, we measure ApoB as part of our cardiovascular risk assessment, and we apply optimal rather than standard target ranges based on longevity research. This is not about alarming people unnecessarily. It is about giving people the most accurate picture of their future health trajectory, early enough that substantial intervention is possible.

2. VO2 Max: The Single Most Powerful Predictor of How Long You Will Live
   VO2 max is the maximum rate at which your body can consume oxygen during exercise. It is a direct measure of cardiorespiratory fitness and arguably the most clinically significant number in all of longevity medicine.

   In a landmark cohort study of 122,007 consecutive patients undergoing exercise treadmill testing at the Cleveland Clinic, cardiorespiratory fitness was inversely associated with all-cause mortality without any observed upper limit of benefit. Extreme cardiorespiratory fitness was associated with the lowest risk-adjusted all-cause mortality compared with all other performance groups.

   

   Comparing someone of low fitness to someone of elite fitness reveals a five-fold difference in mortality over a decade, a gap that exceeds the mortality risk associated with smoking, type 2 diabetes, hypertension, and coronary artery disease.

   In a 46-year follow-up study published in the Journal of the American College of Cardiology, higher midlife cardiorespiratory fitness was associated with longevity in a dose-response dependent manner, with the highest-fit 5% surviving an average of approximately 5 years longer than the lowest-fit 5%.

   At Duro Health, we offer VO2 max testing as a core functional assessment. The result does not just tell you how fit you are today, it gives you a meaningful, motivating, and measurable target to work towards, with a direct and quantifiable impact on how long and how well you are likely to live.

3. HOMA-IR: Catching Metabolic Dysfunction Before It Becomes Disease
   

   Type 2 diabetes does not appear overnight. The metabolic dysfunction that drives it, primarily a progressive loss of the body’s sensitivity to insulin, develops gradually over years, often without any symptoms and without triggering the “abnormal” flags on a standard blood test. By the time a fasting glucose result crosses the diagnostic threshold for diabetes, insulin resistance has typically been present for more than a decade.

   This is where HOMA-IR comes in. The Homeostatic Model Assessment of Insulin Resistance is a calculation derived from two simple fasting blood values: glucose and insulin. Together, they give a picture of how hard your pancreas is working to maintain normal blood sugar levels. A rising HOMA-IR, even within the conventional “normal” range, indicates that insulin is becoming less effective and that compensatory mechanisms are already under strain.

   It is estimated that the insulin-resistant state precedes the onset of type 2 diabetes by approximately 15 years, meaning there is a substantial window during which measurable intervention is possible, provided it is actively assessed. Prospective data from the Verona Diabetes Complications Study showed that HOMA-IR is an independent predictor of cardiovascular disease, with each unit increase in HOMA-IR associated with a significantly higher odds of both prevalent and incident cardiovascular events, even after adjusting for traditional risk factors including sex, age, smoking, lipids, and blood pressure.

   Insulin resistance can be present for years before type 2 diabetes is diagnosed, and during this time it independently increases cardiovascular disease risk through mechanisms including chronic low-grade inflammation, elevated triglycerides, endothelial dysfunction, and accelerated atherosclerosis.

   A standard GP blood test does not routinely include a fasting insulin level, so HOMA-IR is simply never calculated. At Duro Health, it is a routine part of our metabolic assessment. When we identify an elevated HOMA-IR, we have a specific, modifiable target to work on, with a personalised plan that typically centres on nutrition, movement, and sleep. The payoff is not just reduced diabetes risk: it is a meaningful reduction in cardiovascular risk, inflammatory burden, and long-term metabolic decline.

4. Grip Strength: The Simplest Measure You’ve Never Had Done
   

   Grip strength is not a gym metric. It is one of the most powerful, most replicated, and most underutilised clinical measurements in medicine. It takes 30 seconds, requires only a hand-held dynamometer, costs essentially nothing, and tells us a remarkable amount about where your health is headed.

   Grip strength serves as a proxy for overall musculoskeletal health, muscle mass, neuromuscular function, and systemic reserve. Muscle is not just an aesthetic or performance tissue: it is a metabolic organ, deeply integrated with insulin sensitivity, immune function, inflammatory regulation, and the capacity to withstand and recover from illness.

   The evidence base here is striking. In the landmark Prospective Urban Rural Epidemiology (PURE) study of 139,691 participants across 17 countries, grip strength was inversely associated with all-cause mortality, with each 5 kg reduction in grip strength linked to a 16% higher risk of death, a 17% higher risk of cardiovascular death, and increased risk of myocardial infarction and stroke. Critically, grip strength was a stronger predictor of all-cause and cardiovascular mortality than systolic blood pressure.

   A meta-analysis of 42 studies including more than 3 million participants confirmed that grip strength is an independent predictor of all-cause mortality, with each 5 kg decrease in grip strength associated with a 16% increase in risk.

   In a prospective cohort study of very old adults followed over 9.6 years, higher baseline grip strength was independently associated with reduced mortality risk, and men and women whose grip strength declined over time had a significantly higher risk of death than those who maintained or improved it.

   The good news is that muscle strength is highly trainable at any age, and the same interventions that improve grip strength, namely structured resistance training, adequate protein, and quality sleep, also improve insulin sensitivity, bone density, cognitive function, and a host of other longevity-relevant outcomes. Measuring grip strength at Duro Health is not about labelling someone as weak. It is about establishing a baseline, identifying risk early, and giving people a concrete, trackable, motivating target to build towards.

The Three Pillars: Physical, Cognitive, and Emotional Health

At Duro Health, we understand healthspan as a three-pillared concept. There is no point having outstanding physical health without cognitive sharpness, nor either of those without emotional wellbeing. All three are interdependent, and our approach addresses all three with equal seriousness. Investigations, lifestyle planning, and allied health integration all reflect this.

Our Longevity Action Plan, the personalised document each patient receives, brings together advanced biomarker results, functional testing, genetic insights where relevant, and personalised, plain-English recommendations across all three domains. The aim is not to overwhelm but to illuminate: to give you the specific, prioritised, and actionable information that allows you to make wiser, more considered health decisions.

Who Can Benefit From Longevity Medicine?

Duro Health is for anyone who wants to be a participant in their health, not a passenger. You do not need to be unwell, or already health-conscious, or particularly athletic. You need only be curious about what is actually going on inside your body, and motivated to do something about it.

You might be in your 30s and wanting to establish a baseline before risks accumulate. You might be in your 40s or 50s and aware that this is the decade when many chronic disease trajectories begin to diverge. You might be older and determined to extend your healthy, functional years well into the future. Age is never a barrier to optimising your health. There are always improvements that can be made through evidence-based, personalised, and proactive assessments and advice.  

Whatever your life stage, whatever your health status, wherever you are, the best time to start is now.